65,437 trials
Exercise Induced Asthma
Primary: Maximum Post-exercise Percent (%) Fall in FEV1 — 10.57; 13.82 Percent change from baseline — p=0.009
Diabetes Mellitus, Type 2
Primary: Hemoglobin A1c (HbA1c) at 36 Week Endpoint — 7.66; 7.49 percent HbA1c — p=0.097
Smoking Cessation
Primary: Number of Subjects With Four Week Continuous Quit Rate (CQR) — 105; 22 participants — p=<0.0001
Spinal Procedure Requiring Dura Incision
Primary: Watertight Dural Closure — 102; 36 Participants
Pulmonary Disease, Chronic Obstructive · Chronic Bronchitis · Pulmonary Emphysema
Primary: Percentage Change in Exercise Tolerance From Baseline at 2 Weeks — 68; 124 Percentage change — p=0.038
Hepatitis A · Hepatitis B
Primary: Number of Subjects With Anamnestic Response to the Challenge Dose for Anti-hepatitis A (Anti-HAV) Antibodies — 164; 164; 162 Participants
Benign Prostatic Hyperplasia (BPH)
Primary: International Prostate Symptom Score (IPSS) — 21.5; 21.4; -6.5; -3.6 Units on a 0 to 35 scale
Asthma
Primary: Maximum Percent Change From Baseline in Forced Expiratory Volume in One Second (FEV1) Observed up to Two Hours Post Dose (FEV1max%0-2) on Day 22 — 12.849; 9.353…
Sinusitis
Primary: Percentage of Subjects With Clinical Cure (Modified Intent-to-Treat (MITT)) — 78.1; 66.7; 19.2; 33.3 Percentage of subjects — p=0.189
Venous Thromboembolism
Primary: Risk of Venous Thromboembolism (VTE) Between Women Who Use Dienogest/Ethinylestradiol (DNG/EE) and Women Who Use Other Low-dose Combined Oral Contraceptives (COC) — 35…
Multiple Sclerosis
Primary: The Cumulative Number of Newly Gadolinium-enhancing T1-weighted Lesions on Cranial Magnetic Resonance Imaging (MRI)s Through Week 23. — 1.20; 1.00; 2.00; 2.40 Lesions…
Total Knee Arthroplasty
Primary: Sublingual Temperature. — 36.38; 36.73 C
Generalized Anxiety Disorder
Primary: Change in Hamilton Anxiety Rating Scale (HAM-A) Total Scores — -7.6; -6.4 score on scale
Diabetes Mellitus, Type 2
Primary: Patients With Glycosylated Haemoglobin (HbA1c) Value < 7% — 22.4; 8.8 percentage of participants — p=0.0499
Pelvic Inflammatory Disease
Primary: Clinical Response 7 to 14 Days After Completion of Study Drug Therapy in Per Protocol (PP) Population — 152; 155; 42; 35 participants